Pioglitazone reduces major adverse CV events in prediabetes,
In people with insulin resistance, prediabetes or diabetes, pioglitazone is associated with a decreased risk for major adverse cardiovascular events, study data show.
However, pioglitazone may increase risks for heart failure, bone fracture, edema and weight gain, according to the researchers...

http://www.healio.com/endocrinology/diabetes/news/in-the-journals/{684357ff-1177-4862-9fae-2995e93a6032}/pioglitazone-reduces-major-adverse-cv-events-in-prediabetes-diabetes
Like
Comment
Share